DGAP-News: BB BIOTECH AG: Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed
The biotech sector made significant strides, leading the effort against the SARS-CoV-2 virus pandemic through approved mRNA vaccines and therapeutic antibodies.
DGAP-News: BB BIOTECH AG / Key word(s): Annual Results/Dividend BB BIOTECH AG: Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed 22.01.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Media release as of January 22, 2021 Portfolio of BB Biotech AG as of December 31, 2020 Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed During the fourth quarter, profits were also taken on investments including Halozyme, Moderna, Myovant, Crispr Therapeutics and Scholar Rock. The cash was reinvested in targets associated with the strategic portfolio reallocation - focusing on smaller and mid cap portfolio companies. BB Biotech took advantage of market conditions by investing more in Molecular Templates, Arvinas, Generation Bio and Relay Therapeutics. For further information: Investor Relations Media Relations TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28 Company profile Disclaimer
22.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | BB BIOTECH AG |
Schwertstrasse 6 | |
8200 Schaffhausen | |
Switzerland | |
Phone: | +41 52 624 08 45 |
E-mail: | [email protected] |
Internet: | www.bbbiotech.ch |
ISIN: | CH0038389992 |
WKN: | A0NFN3 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Mailand, SIX |
EQS News ID: | 1162360 |
End of News | DGAP News Service |
|
1162360 22.01.2021